Prosecution Insights
Last updated: November 04, 2026
Application No. 18/332,551

BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE

Final Rejection §DP
Filed
Jun 09, 2023
Priority
Dec 11, 2020 — provisional 63/124,395 +2 more
Examiner
O DELL, DAVID K
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tmem16A Limited
OA Round
2 (Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
94%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
780 granted / 1349 resolved
-2.2% vs TC avg
Strong +36% interview lift
Without
With
+35.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
59 currently pending
Career history
1411
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
34.5%
-5.5% vs TC avg
§102
14.5%
-25.5% vs TC avg
§112
30.1%
-9.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1349 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1. This application is a CON of PCT/IB21/00862 12/10/2021; PCT/IB21/00862 has PRO 63/124,395 12/11/2020. Claims 5, 9, 34 are pending. Response to Amendments 2. The rejection of claims 1 and 34 under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention is withdrawn based upon the amendments. The rejection of claim(s) 1 and 34 under 35 U.S.C. 102(a)(2) as being anticipated by Collingwood WO 2020249957 is withdrawn based upon the amendments. The rejection of claims 1, 34 under 35 U.S.C. 102(a)(1) as being anticipated by Goeker Eur. J. Med Chem 2005, 40, 1062-1069 is withdrawn based upon the amendments. The rejection of claim(s) 1, 4 under 35 U.S.C. 102(a)(1) as being anticipated by the STN-Chemical Database Registry for N-Cyclohexyl-2-(phenylmethyl)-1H-benzimidazole-6-carboxamide, RN 2199776-37-7 entered into STN: 27 Mar 2018 is withdrawn based upon the amendments. The rejection of claim(s) 5 and 9 under 35 U.S.C. 103 as being unpatentable over Collingwood WO 2020249957 as applied to claims 1, 4, 34 above and further in view of Wislicenus, J. “Adolph Strecker’s Short Textbook of Organic Chemistry” 1881, Spottiswoode: London, pages 38-39 is withdrawn based upon a statement pursuant to 35 U.S.C. 102(b)(2)(C) establishing that, not later than the effective filing date of the claimed invention, the subject matter disclosed and the claimed invention were either owned by the same person or subject to an obligation of assignment to the same person or subject to a joint research agreement. See generally MPEP § 717.02. Collingwood WO 2020249957 is no longer prior art. The rejection of claim 1 on the ground of nonstatutory double patenting as being unpatentable over claim 1-4, 6-7 of U.S. Patent No. 12,552,770 is withdrawn based upon the amendments. The rejection of claim 34 under 35 U.S.C. 103 as being unpatentable over STN-Chemical Database Registry for N-Cyclohexyl-2-(phenylmethyl)-1H-benzimidazole-6-carboxamide, RN 2199776-37-7 entered into STN: 27 Mar 2018 as applied to claim 1 and 4 above is withdrawn since claim 34 now depends upon claim 9 which was not rejected under this ground. The rejection of claims 1, 34 on the judicially-created basis that it contains an improper Markush grouping of alternatives is withdrawn based upon the amendments. The rejection of claims 5 and 9 and now claim 34 (based upon a change in dependency from claim 1 to claim 9) on the ground of nonstatutory double patenting as being unpatentable over claims 1-4, 6-7 of U.S. Patent No. 12,552,770 further in view of Wislicenus, J. “Adolph Strecker’s Short Textbook of Organic Chemistry” 1881, Spottiswoode: London, pages 38-39 is maintained. Applicant’s representative’s arguments submitted on August 24, 2026 have been fully considered but are unpersuasive. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. 3. Claims 5, 9, 34 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4, 6-7 of U.S. Patent No. 12,552,770 further in view of Wislicenus, J. “Adolph Strecker’s Short Textbook of Organic Chemistry” 1881, Spottiswoode: London, pages 38-39. Although the claims at issue are not identical, they are not patentably distinct from each other because the patent claims are drawn to position isomers and alkyl homologs. The compound in claim 9, PNG media_image1.png 191 477 media_image1.png Greyscale is a position isomer of the compound Example 2 in the patent claims. This compound only differs by the point of attachment of the adamantane as 1 or 2. Collingwood also teaches a number of additional compounds that are similar to those of claims 5 and 9 including: PNG media_image2.png 204 549 media_image2.png Greyscale This compound is simply an alkyl homolog of the claimed compound in claim 9: PNG media_image3.png 198 507 media_image3.png Greyscale , where the size of the ring was extended by one methylene unit. The elected species is a compound where the ring has contracted by one methylene as compared to prior art compound Example 24.2 as shown below: PNG media_image4.png 199 478 media_image4.png Greyscale The lower homolog where the ring is cyclopentyl is also disclosed by Collingwood on page 114: PNG media_image5.png 212 591 media_image5.png Greyscale Ascertaining the differences between the prior art and the claims at issue. The instant claims are drawn to minor variations of the disclosed species of the prior art including position isomers and alkyl homologs. Resolving the level of ordinary skill in the pertinent art and Considering objective evidence present in the application indicating obviousness or nonobviousness: Positional isomers, having the same radical on different positions of the molecule, are prima facie obvious, and require no secondary teaching. The experienced Ph.D. synthetic organic chemist, who would make the compounds, would be motivated to prepare these position isomers based on the expectation that such close analogues would have similar properties and upon the routine nature of such position isomer experimentation in the art of medicinal chemistry. It would be routine for the chemist to vary the point of attachment in order to increase potency. Homologs have long been known to exhibit similar properties as evidenced by page 38 of Wislicenus: HOMOLOGY AND HOMOLOGOUS SERIES, 48. In opposition to the remarkable differences between organic bodies of like molecular formulae, is the fact that bodies of different molecular composition frequently exhibit great similarity in all their chemical and physical properties. The compounds in which these analogies are most marked are those whose formulae differ by CH2, or a whole multiple thereof, nCH2, and whose molecular weights differ therefore by ± 14n.…This analogy of structure is especially shown in the fact that like reagents produce like changes, and further that the resulting products of such changes agree in properties, but differ in composition by CH2. Such bodies are termed homologous compounds. They form members of a natural family of bodies which can be arranged according to their increasing contents of carbon. The similarity of physical properties between the members of a homologous series is greater the nearer they stand to one another on such a list that is, the less they differ in chemical composition. Analogs differing only in a single methylene, are prima facie obvious, and require no secondary teaching, see In re Coes, Jr. (CCPA 1949) 173 F2d 1012, 81 USPQ 369. In re Shetty, 195 USPQ 753, In re Wilder, 195 USPQ 426, and Ex parte Greshem, 121 USPQ 422 all feature a compound with a two carbon link rejected over a compound with a one carbon link. Similarly In re Chupp, 2 USPQ 2nd 1437 and In re Coes, 81,USPQ 369 have a one-carbon link unpatentable over a two-carbon link. Ex parte Ruddy, 121 USPQ 427 has a three-carbon link unpatentable over a one-carbon link. Ex parte Nathan, 121 USPQ 347 found the insertion of an ethylene linkage obvious. The variation was per se obvious in all these cases and did not require a specific teaching. In this case Collingwood made various homologs and the species claimed just fill additional gaps in the disclosed homologous series. Conclusion 4. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID K O'DELL whose telephone number is (571)272-9071. The examiner can normally be reached on Monday - Friday 9:30 - 7:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached on 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. /DAVID K O'DELL/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jun 09, 2023
Application Filed
Apr 20, 2026
Non-Final Rejection mailed — §DP
Aug 24, 2026
Response Filed
Sep 25, 2026
Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780839
Tricyclic Derivatives Useful As PARP7 Inhibitors
3y 2m to grant Granted Nov 03, 2026
Patent 12767983
Asymmetric Rhodamine Dye and Use Thereof in Biological Assays
5y 4m to grant Granted Oct 20, 2026
Patent 12760051
METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND
3y 9m to grant Granted Oct 13, 2026
Patent 12760049
METAL-ASSISTED DELAYED FLUORESCENT EMITTERS EMPLOYING PYRIDO-PYRROLO-ACRIDINE AND ANALOGUES
3y 4m to grant Granted Oct 13, 2026
Patent 12753146
INDUSTRIAL SYNTHESIS OF SERINOL
3y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
94%
With Interview (+35.9%)
2y 9m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1349 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month